

Cereno Scientific Confirms that Members of Management and Chair of Board have Acquired Shares for a Total of Over 1.5 MSEK

Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced, that several of members in management including the CEO, CSO, CMO and Head of R&D, as well as the Chair of the Board, have acquired shares in the company. The total number of purchased shares is 292,061 B-shares, corresponding to a purchase amount of over 1.5 million SEK.

Sten R. Sörensen, CEO, has bought a total of 190,543 B-shares in the company in 5 transactions during July 2-8, 2026. The shares were purchased to an average price of 5.28 SEK per share and the total purchase amount is approximately 1,000,000 SEK. After the purchase, Sörensen owns a total of 2,192,722 B-shares, and 5,000,000 warrants.

Björn Dahlöf, Chief Scientific Officer, has bought a total of 35,978 B-shares in 2 transactions during July 2-7, 2026. The shares were purchased to an average price of 5.31 SEK per share and the total purchase amount is approximately 191,000 SEK. After the purchase, Dahlöf owns 123,920 A-shares, 2,052,830 B-shares, and 2,500,000 warrants.

Rahul Agrawal, Chief Medical Officer and Head of R&D, has bought 18,081 B-shares at a price of 5.53 SEK per share, corresponding to a purchase amount of approximately 100,000 SEK. The shares were purchased on July 2, 2026. After the purchase, Agrawal owns a total of 18,081 B-shares, and 2,000,000 warrants.

Jeppe Øvlesen, Chair of the Board, has bought a total of 47,459 B-shares in 2 transactions reported on July 7, 2026. The shares were purchased to an average price of 5.11 SEK per share and the total purchase amount is approximately 243,000 SEK. After the purchase, Øvlesen owns 132,693 B-shares, and 1,000,000 warrants.

“Cereno is in a stronger position than ever, with clear momentum across our pipeline and important value-driving milestones ahead. The share purchases by management and Chair of the Board demonstrate our strong confidence in the company’s strategy, partnering potential and ability to deliver on the opportunities ahead,” said Sten R. Sörensen, CEO of Cereno Scientific.

The purchases were made on Nasdaq First North Growth Market.

For further information, please contact:

Tove Bergenholt, Head of IR & Communications

Email: tove.bergenholt@cerenoscientific.com

Phone: +46 73- 236 62 46

About Cereno Scientific AB

Cereno Scientific is pioneering treatments to enhance and extend life. The company's innovative pipeline offers disease-modifying drug candidates to empower people suffering from rare cardiovascular and pulmonary diseases to live life to the fullest.

Lead candidate CS1 is an HDAC inhibitor that works through epigenetic modulation and represents a novel therapeutic approach by targeting the root mechanisms of the pulmonary arterial hypertension (PAH). CS1 is a well-tolerated oral therapy with a favorable safety profile that has shown encouraging efficacy signals in a Phase IIa trial in patients with PAH, including improvements in right heart function, functional class and patient quality of life, with early signs consistent with reverse vascular remodeling. An Expanded Access Program confirmed CS1 to be well-tolerated with a favorable safety profile over 12 months of treatment and showed that a majority of patients completing treatment maintained or improved clinical status. CS014 is a new chemical entity and HDAC inhibitor with a multimodal mechanism of action as an epigenetic modulator having the potential to address the underlying pathophysiology of a range of cardiovascular and pulmonary diseases with high unmet needs. CS014 showed favorable safety and tolerability profile in Phase I, and is being advanced through a streamlined, FDA-aligned pathway toward Phase IIb in pulmonary hypertension associated with interstitial lung disease (PH-ILD). Cereno Scientific is also advancing the preclinical program CS585, an oral, highly potent and selective prostacyclin (IP) receptor agonist shown to prevent thrombosis without increased bleeding risk, currently being evaluated in antiphospholipid syndrome (APS).

The Company is headquartered in GoCo Health Innovation City, in Gothenburg, Sweden, and has a US subsidiary; Cereno Scientific Inc. based in Kendall Square, Boston, Massachusetts, US. Cereno Scientific is listed on the Nasdaq First North (CRNO B). The Company's Certified Adviser is DNB Carnegie Investment Bank AB, certifiedadviser@carnegie.se. More information can be found on www.cerenoscientific.com.